Advertisement

Topics

Virion Biotherapeutics Company Profile

07:42 EST 12th December 2018 | BioPortfolio

Virion Biotherapeutics seeks to transform the management of respiratory viral infections with the development of its proprietary Therapeutic Interfering Particles (TIPs). These first-in-class biologicals enhance a naturally-occurring dual mechanism that interferes with viral replication, preventing infection and stopping disease, enabling treatment of the broad spectrum of respiratory virus infections. Virion was founded in 2017 based on the pioneering work on viral replication and interference of Professor Nigel Dimmock and Professor Andrew Easton. The company is led by an experienced management team with a track record in biotech start-ups and infectious disease drug development, and its founding investor is Abingworth. Further information can be found at www.virionbiotx.com.


News Articles [226 Associated News Articles listed on BioPortfolio]

Virion Biotherapeutics Demonstrates Preclinical Proof-of-Concept for First Therapeutic Interfering Particle Candidate in Respiratory Virus Infections

--Data presented at 6th ISIVR-AVG Conference-- --Company announces Penelope Ward joins as Chief Medical Officer-- Virion Biotherapeutics today presented in vivo data ...

Virion Appoints Vanessa King as President & CEO and Isabel Najera as CSO

Building Team to Transform Respiratory Virus Infection Management using Therapeutic Interfering Particles Virion Biotherapeutics announced today the appointments of Vanessa Ki...

Human medicines European public assessment report (EPAR): Intanza, influenza vaccine (split virion, inactivated), Revision: 18, Withdrawn

Asterias Biotherapeutics to merge with BioTime

US-based biotechnology firms BioTime and Asterias Biotherapeutics have entered into a definitive merger agreement to form an integrated company focussed...Read More... The post Asterias Biotherapeutic...

Codexis Appoints Biotherapeutics R&D VP

Dr. Alaoui will be responsible for the biotherapeutics discovery pipeline and acceleration of drug candidates to the clinic

Cancer Research UK launches new research hub for biotherapeutics

Cancer Research UK has launched a global centre of excellence in London to facilitate research on biotherapeutics as a treatment...Read More... The post Cancer Research UK launches new research hub fo...

Pall and Celltheon form strategic biotherapeutics partnership

This partnership will deliver integrated manufacturing solutions for customers developing biotherapeutics

Improving understanding of biotherapeutics and biosimilars

Additional information on biosimilars and biotherapeutics have been published in Europe.

Drugs and Medications [14 Associated Drugs and Medications listed on BioPortfolio]

Plasmanate [TALECRIS BIOTHERAPEUTICS, INC.]

Plasma Protein Fraction (Human) 5%, USPPlasmanate®

Gamastan s/d [TALECRIS BIOTHERAPEUTICS, INC.]

Immune Globulin (Human)GamaSTAN™ S/DSolvent/Detergent Treated

Plasbumin [TALECRIS BIOTHERAPEUTICS, INC.]

Albumin (Human) 5%, USPPlasbumin ®-5

Plasbumin [TALECRIS BIOTHERAPEUTICS, INC.]

Albumin (Human) 5%, USPPlasbumin ®-5

Plasbumin [TALECRIS BIOTHERAPEUTICS, INC.]

Albumin (Human) 20%, USPPlasbumin®-20

PubMed Articles [64 Associated PubMed Articles listed on BioPortfolio]

Synthetic Biology and Engineered Live Biotherapeutics: Toward Increasing System Complexity.

Recent advances in synthetic biology and biological system engineering have allowed the design and construction of engineered live biotherapeutics targeting a range of human clinical applications. In ...

Cell Penetration Profiling Using the Chloroalkane Penetration Assay.

Biotherapeutics are a promising class of molecules in drug discovery, but they are often limited to extracellular targets due to their poor cell penetration. High-throughput cell penetration assays ar...

Site-Specific Glycosylation of Virion-Derived HIV-1 Env Is Mimicked by a Soluble Trimeric Immunogen.

Many broadly neutralizing antibodies (bnAbs) against HIV-1 recognize and/or penetrate the glycan shield on native, virion-associated envelope glycoprotein (Env) spikes. The same bnAbs also bind to rec...

Live bacterial biotherapeutics in the clinic.

Development of infectious cDNA clones of Grapevine leafroll-associated virus 3 and analyses of the 5' non-translated region for replication and virion formation.

Infectious cDNA clones were developed for Grapevine leafroll-associated virus 3 (GLRaV-3, genus Ampelovirus, family Closteroviridae). In vitro RNA transcripts generated from cDNA clones showed replica...

Clinical Trials [71 Associated Clinical Trials listed on BioPortfolio]

A Clinical Trial With Influenza A/H1N1 Vaccines

A single center, stratified, randomized and double-blind phase IV clinical trial is to be conducted in healthy elders (equal to or more than 61 years), adults (18-60 years), adolescents (1...

Study of Inactivated, Split-Virion Influenza Vaccine Administered by Intradermal Route Versus Vaxigrip® in Adults

This is a follow-up of a previous dose-ranging study aimed at investigating 2 doses of the trivalent inactivated split virion influenza vaccine when administered by intradermal route with ...

Phase 3 Immunogenicity and Safety Study of an Inactivated H5N1 Influenza Vaccine (Whole Virion, Vero Cell Derived)

The objectives of this study are to assess the immune response as well as the safety and tolerability of an H5N1 influenza vaccine in an adult and elderly population. Further, the study wi...

Safety and Immunogenicity of H5N1 Adjuvanted, Inactivated, Split-Virion Pandemic Influenza Vaccine in Healthy Adults

The purpose of this study is to test different adjuvanted vaccine formulations as a two-dose schedule in immunologically naïve adults against one vaccine formulation without adjuvant in t...

A Clinical Trial of Split-virion Influenza A/H1N1 Vaccines

A single center, Open-Label phase IV clinical trial is to be conducted in healthy elders (equal to or more than 61 years to evaluate the immunogenicity and safety of Sinovac's 15μg H1N1 i...

Companies [106 Associated Companies listed on BioPortfolio]

Virion Biotherapeutics

Virion Biotherapeutics seeks to transform the management of respiratory viral infections with the development of its proprietary Therapeutic Interfering Particles (TIPs). These fi...

Axial Biotherapeutics

Axial Biotherapeutics is a biopharmaceutical company harnessing the link between the human gut microbiome and the central nervous system to develop a new class of biotherapeutics ...

Napro Biotherapeutics Incorporated

NaPro BioTherapeutics, Inc. is a natural product pharmaceutical company focused primarily on the development, manufacture and commercializa tion of paclitaxel, a naturally-occurring anti-cancer agent ...

Sephos Biotherapeutics

Sephos Biotherapeutics is a privately owned company focused on designing drugs for the treatment of cancer stem cells where the structure and biological activity of the drugs have...

Talecris Biotherapeutics Holdings Inc.

Talecris Biotherapeutics (Nasdaq: TLCR) is a global biotherapeutic and biotechnology company that discovers, develops and produces critical care treatments for people with life-threatening disorders i...

More Information about "Virion Biotherapeutics" on BioPortfolio

We have published hundreds of Virion Biotherapeutics news stories on BioPortfolio along with dozens of Virion Biotherapeutics Clinical Trials and PubMed Articles about Virion Biotherapeutics for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Virion Biotherapeutics Companies in our database. You can also find out about relevant Virion Biotherapeutics Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology Products
BioPortfolio lists over 550 biotechnology products - please open http://www.bioportfolio.com/channels?category_id=5 Direct topic pages: Actos Advair Biopharmaceuticals Biosimilars Biotherapeutics GMO Crops Lipitor ...

Respiratory
Asthma COPD Cystic Fibrosis Pneumonia Pulmonary Medicine Respiratory Respiratory tract infections (RTIs) are any infection of the sinuses, throat, airways or lungs.  They're usually caused by viruses, but they can also ...

Infectious-diseases
Antiretroviral Therapy Clostridium Difficile Ebola HIV & AIDS Infectious Diseases Influenza Malaria Measles Sepsis Swine Flu Tropical Medicine Tuberculosis Infectious diseases are caused by pathogenic...


Corporate Database Quicklinks



Searches Linking to this Company Record